<DOC>
	<DOCNO>NCT03067935</DOCNO>
	<brief_summary>Celldex endeavor make investigational product available patient life-threatening disease exhaust treatment option reasonable expectation benefit risk . Requests expand access glembatumumab vedotin patient gpNMB express triple negative breast cancer consider .</brief_summary>
	<brief_title>Individual Patient Expanded Access-Glembatumumab Vedotin</brief_title>
	<detailed_description />
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . The patient 18 year age old . 2 . The patient histologically confirm , gpNMB expressing , metastatic triplenegative breast cancer 3 . Overexpression gpNMB least one tumor sample determine Sponsor approve laboratory use IHC method 4 . The patient abnormal organ function , active autoimmune disease , active infection additional concurrent condition would compromise patient 's ability safely receive glembatumumb vedotin . 5 . The patient eligible access ongoing glembatumumab vedotin clinical trial 6 . The patient qualify , access , comparable satisfactory alternative therapy triple negative breast cancer . 7 . The patient able read understand , sign patient inform consent form , outlines nature propose treatment anticipated benefit risk treatment glembatumumab vedotin . 1 . History allergic reaction attribute compound similar composition glembatumumab vedotin , MMAE , dolastatin auristatin . 2 . Pregnant breastfeed woman , woman men willing use effective contraception time sign informed consent two month last dose glembatumumab vedotin treatment . 3 . The patient previously treat glembatumumab vedotin previously enrol METRIC trial ( regardless arm randomize ) . 4 . Any underlying medical condition , investigator 's Sponsor 's opinion , make administration Glembatumumab vedotin hazardous patient , would obscure interpretation adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>